Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
4.
J Thromb Thrombolysis ; 42(4): 586-92, 2016 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-27379499

RESUMO

Differential diagnosis between thrombotic thrombocytopenic purpura (TTP) and other thrombotic microangiopathies (TMA) is usually difficult because of frequently overlapping clinical presentations. Severely depressed ADAMTS13 activity (<10 %) seems distinctive for TTP because of its pathogenetic role. However a long debate exists in the literature about its sensibility and specificity. Our aim was to search for clinical differences between TMA patients referred to our laboratory, comparing them for protease activity <10 versus ≥10 %. ADAMTS13 activity ≥10 % patients (n = 73) showed a higher prevalence of drug- (p = 0.005) and cancer-associated (p < 0.001) TMA. Mean platelet count and renal dysfunction prevalence was lower (p < 0.001), while neurological impairment was more frequent (p = 0.001) in the <10 % ADAMTS13 activity group (n = 109), confirming previous literature findings. When taken neurological manifestations singularly, epilepsy (p = 0.04), focal motor deficit (p < 0.001) and cranial nerve palsy (p = 0.007) were more frequent in the <10 % activity group. In our case series, a <10 % ADAMTS13 activity depicts a group of patients with clinical features similar to TTP patients. Focal motor impairment or epileptic manifestations could further address toward a TTP diagnosis. Studies about treatment efficacy and follow-up are advised to determine whether laboratory findings can guide therapeutic decisions.


Assuntos
Proteína ADAMTS13/sangue , Doenças dos Nervos Cranianos/sangue , Epilepsia Motora Parcial/sangue , Microangiopatias Trombóticas/sangue , Doença Aguda , Adulto , Idoso , Doenças dos Nervos Cranianos/etiologia , Epilepsia Motora Parcial/etiologia , Feminino , Humanos , Nefropatias/sangue , Masculino , Volume Plaquetário Médio , Pessoa de Meia-Idade , Neoplasias/sangue , Microangiopatias Trombóticas/complicações
5.
Diabetes Res Clin Pract ; 104(3): 323-8, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24513120

RESUMO

The lesions of diabetic nephropathy have been considered to be irreversible. Pancreas transplantation is the only available treatment able to restore long-term normoglycemia without exposing the patients to the risks of severe hypoglycemia; thus allowing testing the effects of very long-term euglycemia in preventing, halting and reversing diabetic nephropathy. Pancreas transplantation, performed simultaneously or shortly after kidney transplantation in patients with type 1 diabetes prevents the recurrence of diabetic glomerulopathy lesions. To test whether diabetic nephropathy lesions are reversible in humans, we studied renal structure before and 5 and 10 years after pancreas transplantation alone in eight non-uremic patients with long-term type 1 diabetes, who had mild to advanced diabetic nephropathy lesions at the time of transplantation. We observed that, despite prolonged normoglycemia, diabetic glomerular lesions were not significantly changed at 5 years post pancreas transplantation. In contrast, glomerular lesions were markedly improved after 10 years; indeed in most patients glomerular structure was normal at 10-year follow-up. We reported similar findings also for tubular and interstitial lesions. Thus this study demonstrated, for the first time in humans, that the lesions of diabetic nephropathy are reversible and that the kidney can undergo substantial architectural remodeling upon long-term normalization of the diabetic milieu.


Assuntos
Diabetes Mellitus/fisiopatologia , Nefropatias Diabéticas/prevenção & controle , Rim/patologia , Transplante de Pâncreas , Prevenção Secundária , Nefropatias Diabéticas/etiologia , Humanos
6.
Circulation ; 129(9): 999-1008, 2014 Mar 04.
Artigo em Inglês | MEDLINE | ID: mdl-24352521

RESUMO

BACKGROUND: Microvascular renal and retinal diseases are common major complications of type 2 diabetes mellitus. The relation between plasma lipids and microvascular disease is not well established. METHODS AND RESULTS: The case subjects were 2535 patients with type 2 diabetes mellitus with an average duration of 14 years, 1891 of whom had kidney disease and 1218 with retinopathy. The case subjects were matched for diabetes mellitus duration, age, sex, and low-density lipoprotein cholesterol to 3683 control subjects with type 2 diabetes mellitus who did not have kidney disease or retinopathy. The study was conducted in 24 sites in 13 countries. The primary analysis included kidney disease and retinopathy cases. Matched analysis was performed by use of site-specific conditional logistic regression in multivariable models that adjusted for hemoglobin A1c, hypertension, and statin treatment. Mean low-density lipoprotein cholesterol concentration was 2.3 mmol/L. The microvascular disease odds ratio increased by a factor of 1.16 (95% confidence interval, 1.11-1.22) for every 0.5 mmol/L (≈1 quintile) increase in triglycerides or decreased by a factor of 0.92 (0.88-0.96) for every 0.2 mmol/L (≈1 quintile) increase in high-density lipoprotein cholesterol. For kidney disease, the odds ratio increased by 1.23 (1.16-1.31) with triglycerides and decreased by 0.86 (0.82-0.91) with high-density lipoprotein cholesterol. Retinopathy was associated with triglycerides and high-density lipoprotein cholesterol in matched analysis but not significantly after additional adjustment. CONCLUSIONS: Diabetic kidney disease is associated worldwide with higher levels of plasma triglycerides and lower levels of high-density lipoprotein cholesterol among patients with good control of low-density lipoprotein cholesterol. Retinopathy was less robustly associated with these lipids. These results strengthen the rationale for studying dyslipidemia treatment to prevent diabetic microvascular disease.


Assuntos
HDL-Colesterol/sangue , Diabetes Mellitus Tipo 2/complicações , Nefropatias Diabéticas/epidemiologia , Retinopatia Diabética/epidemiologia , Internacionalidade , Triglicerídeos/sangue , Idoso , Biomarcadores/sangue , Estudos de Casos e Controles , Diabetes Mellitus Tipo 2/sangue , Nefropatias Diabéticas/sangue , Nefropatias Diabéticas/etiologia , Retinopatia Diabética/sangue , Retinopatia Diabética/etiologia , Dislipidemias/prevenção & controle , Feminino , Humanos , Hipolipemiantes/uso terapêutico , Incidência , Masculino , Microvasos/fisiopatologia , Pessoa de Meia-Idade , Análise Multivariada , Fatores de Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...